biorxiv: Two ingredients in HIV drugs can effectively inhibit SARS-CoV-2 polymerases.

April 13, 2020 / / SARS-CoV-2 is a member of the coronavirus family and is the culprit of the current COVID-19 pandemic.
Researchers from Columbia University and the University of Wisconsin-Madison have previously demonstrated that four nucleotide analogors (especially the active triphosphate forms of sophibwe, Alovding, laminated nitrogen thoraphenoline, and tinofoviraphenolamine) inhibit RNA polymerases (RdRp) that rely on SARS-CoV-2 RNA.
photo source: bioRxiv Novovir and Entruthabin are two components of DESCOVY and TRUVADA, two FDA-approved pre-exposure probing (PrEP) drugs used to prevent HIV infection.
this is a prevention method, i.e. HIV-negative (but high-risk groups that may be infected with the virus) individuals take a combined daily dose, can reduce the chance of HIV infection.
PrEP can stop the replication and spread of HIV in the body.
researchers report in a study published in bioRxiv entitled "Triphosphates of The Two Components in DESCOVY and TRUVADA are Restors of the SARS-CoV-2 Polymerase" that the two components in DESCOVY and TRUVADA can be used as an end to the reaction of SARS-CoV-2 Rd Rp.
, the researchers believe these results provide a molecular basis for evaluating the potential of DESCOVY and TRUVADA as COVID-19 agents.
() Reference: Steffen Jockusch et al. Triphosphates of The Two Components in DESCOVY and TRUVADA are Resors of the SARS-CoV-2 Polymerase. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.04.03.022939.